TherapeuticsMD Announces Closing of its Underwritten Public Offering and Concurrent Registered Direct Offering of Common Stock

Published: Aug 06, 2018

Aug. 6, 2018 20:05 UTC

BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the closing of its previously announced $65 million underwritten public offering of common stock, at a price to the public of $5.10 per share, and concurrent $20 million registered direct offering of common stock to a strategic investor at a price of $5.10 per share. In connection with the underwritten public offering, TherapeuticsMD granted the underwriters an option to purchase up to an additional 1,911,764 shares of common stock at the public offering price less the underwriting discount, which option was exercised in full and closed. TherapeuticsMD received net proceeds from the offerings of approximately $90.0 million, after deducting underwriting discounts and offering expenses payable by TherapeuticsMD. All of the shares in the offerings were sold by TherapeuticsMD.

TherapeuticsMD intends to use the proceeds of the offerings to fund a portion of the costs for the commercial launch of its recently FDA approved product, IMVEXXY™ (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, due to menopause, and to fund a portion of the costs for pre-commercialization and commercialization activities for TX-001HR, its bio-identical hormone therapy combination of 17ß-estradiol and progesterone in a single, oral softgel drug candidate, for the treatment of moderate to severe vasomotor symptoms due to menopause, and its one-year vaginal contraceptive system candidate in-licensed from the Population Council.

Goldman Sachs & Co. LLC acted as bookrunner for the underwritten public offering. Cantor Fitzgerald & Co. acted as joint bookrunning manager for the underwritten public offering. The registered direct offering was made without an underwriter, placement agent, broker or dealer.

TherapeuticsMD filed shelf registration statements on Form S-3 with the Securities and Exchange Commission (the “SEC”) with respect to the offerings. Preliminary prospectus supplements and accompanying prospectuses related to the offerings were filed with the SEC on July 31, 2018. Final prospectus supplements and accompanying prospectuses relating to the offerings were filed with the SEC on August 2, 2018. TherapeuticsMD’s SEC filings are available to the public from the SEC’s website at www.sec.gov. Copies of the prospectus supplements and the accompanying prospectuses relating to these offerings may also be obtained by contacting Goldman Sachs & Co. LLC, Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing Prospectus-ny@ny.email.gs.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 6th Floor New York, New York 10022 or by emailing prospectus@cantor.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative healthcare company focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning/ reproductive health and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues.

Forward-Looking Statements

This press release by TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that TherapeuticsMD intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,” “plans,” “will,” “expects,” “estimates,” “projects,” “positioned,” “strategy” and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and TherapeuticsMD undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of TherapeuticsMD’s control, that may cause actual results to differ materially, including the risks and uncertainties associated with market conditions, risks and uncertainties associated with TherapeuticsMD’s business and finances in general and other risks described in the sections titled “Risk Factors” in TherapeuticsMD’s filings with the SEC, including its most recent Annual Report on Form 10-K, the prospectus supplements with respect to the offerings and other filings with the SEC.

 

Contacts

TherapeuticsMD, Inc.
Investor Contact:
Nichol Ochsner, 561-961-1900 Ext. 2088
Vice President, Investor Relations
nochsner@TherapeuticsMD.com

 
 

Source: TherapeuticsMD, Inc.

Back to news